Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07811193) titled 'A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Vividion Therapeutics, Inc.

Condition: Colorectal Adenocarcinoma

Intervention: Drug: VVD-133214

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 15, 2026

Target Sample Size: 140

Countries of Recruitment...